Your browser is no longer supported. Please, upgrade your browser.
UTHR [NASD]
United Therapeutics Corporation
Index- P/E25.17 EPS (ttm)6.16 Insider Own0.10% Shs Outstand46.67M Perf Week-0.62%
Market Cap7.24B Forward P/E13.06 EPS next Y11.88 Insider Trans-96.10% Shs Float46.06M Perf Month7.59%
Income340.10M PEG0.83 EPS next Q2.26 Inst Own- Short Float9.91% Perf Quarter18.09%
Sales1.29B P/S5.62 EPS this Y91.50% Inst Trans-3.40% Short Ratio8.28 Perf Half Y66.97%
Book/sh26.69 P/B5.81 EPS next Y23.83% ROA17.00% Target Price145.93 Perf Year51.64%
Cash/sh14.90 P/C10.40 EPS next 5Y30.40% ROE26.90% 52W Range84.63 - 164.38 Perf YTD19.74%
Dividend- P/FCF23.51 EPS past 5Y79.20% ROI25.40% 52W High-5.68% Beta1.39
Dividend %- Quick Ratio1.80 Sales past 5Y29.10% Gross Margin90.20% 52W Low83.21% ATR5.25
Employees706 Current Ratio1.90 Sales Q/Q19.90% Oper. Margin41.80% RSI (14)66.62 Volatility5.20% 3.41%
OptionableYes Debt/Eq0.10 EPS Q/Q461.70% Profit Margin26.40% Rel Volume0.80 Prev Close155.58
ShortableYes LT Debt/Eq0.00 EarningsFeb 24 BMO Payout0.00% Avg Volume551.36K Price155.05
Recom2.60 SMA204.33% SMA5010.70% SMA20031.92% Volume441,700 Change-0.34%
Feb-26-15Reiterated H.C. Wainwright Buy $150 → $175
Nov-03-14Downgrade Argus Buy → Hold
Oct-15-14Upgrade Standpoint Research Hold → Buy $144
Aug-29-14Reiterated Standpoint Research Buy $118 → $140
Jul-30-14Reiterated H.C. Wainwright Buy $120 → $150
Apr-07-14Upgrade Standpoint Research Hold → Buy $118
Feb-26-14Reiterated RBC Capital Mkts Sector Perform $80 → $90
Feb-26-14Reiterated Ladenburg Thalmann Buy $138 → $135
Dec-31-13Reiterated Argus Buy $120 → $130
Dec-23-13Upgrade Ladenburg Thalmann Neutral → Buy $138
Dec-02-13Reiterated Argus Buy $85 → $110
Aug-05-13Reiterated Argus Buy $75 → $85
Jul-30-13Downgrade Standpoint Research Buy → Hold
Jun-20-13Upgrade Standpoint Research Hold → Buy
May-15-13Downgrade Standpoint Research Buy → Hold
Mar-25-13Reiterated Ladenburg Thalmann Buy $69 → $63
Feb-27-13Reiterated RBC Capital Mkts Sector Perform $45 → $50
Aug-03-12Downgrade Standpoint Research Buy → Hold
Apr-27-12Downgrade Canaccord Genuity Buy → Hold
Mar-26-12Initiated Canaccord Genuity Buy $56
Feb-28-15 01:04PM  UNITED THERAPEUTICS CORP Financials EDGAR Online Financials
Feb-26-15 07:08PM  10-K for United Therapeutics Corp. Company Spotlight
Feb-25-15 02:59PM  Stocks Mixed; United Therapeutics Jumps To New High at Investor's Business Daily
10:40AM  United Therapeutics Beats on Q4 Earnings & Revenues - Analyst Blog Zacks
06:00AM  United Therapeutics Corporation To Present At The Cowen And Company 35th Annual Healthcare Conference PR Newswire
Feb-24-15 06:17PM  Jazz Pharma Tops, But Stock Falls On Guidance Investor's Business Daily
11:58AM  United Therapeutics beats Street 4Q forecasts AP
10:04AM  United Therapeutics Blood Pressure Drug Lifts Q4 at Investor's Business Daily
07:07AM  Q4 2014 United Therapeutics Corp Earnings Release - Before Market Open CCBN
06:15AM  UNITED THERAPEUTICS CORP Files SEC form 10-K, Annual Report EDGAR Online
06:14AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:00AM  United Therapeutics Corporation Reports 2014 Fourth Quarter And Annual Financial Results PR Newswire
Feb-18-15 04:39PM  Wednesday's Market Recap Yahoo Finance Contributors
Feb-17-15 06:00AM  United Therapeutics Corporation To Announce Fourth Quarter And Annual 2014 Financial Results Before Market Open On Tuesday, February 24, 2015 PR Newswire
Feb-05-15 06:32PM  Hot Growth Stocks: What Sectors Lead 2015 Now? at Investor's Business Daily
Jan-16-15 06:44PM  Ulta Among IBD 50 Stocks Setting Up In Shaky Market at Investor's Business Daily
02:20PM  Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog Zacks
Jan-15-15 05:33PM  NetEase, Other Leading Stocks Break Out To New Highs at Investor's Business Daily
12:50PM  Biotech Stock United Therapeutics Tests New Buy Point at Investor's Business Daily
Jan-06-15 09:50PM  United Therapeutics Corporation To Present At 33rd Annual J.P. Morgan Healthcare Conference PR Newswire
01:03PM  UPDATE: Barclays Initiates Coverage On United Therapeutics Benzinga
Jan-05-15 07:14PM  UPDATE: BTIG Initiates Coverage On United Therapeutics Benzinga
Dec-31-14 06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
06:00AM  United Therapeutics Announces Signing Of Agreement For New Remodulin Delivery System PR Newswire
Dec-24-14 11:48AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
11:26AM  United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin PR Newswire
Dec-19-14 05:20PM  United Therapeutics Lung Drug Keeps Going And Going at Investor's Business Daily
Dec-17-14 06:02AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princ EDGAR Online
06:00AM  United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change PR Newswire
Dec-11-14 11:48AM  Can United Therapeutics find a remedy for recent resistance? at Investor's Business Daily
Dec-08-14 01:25PM  Stocks Fall To Session Lows: GoPro Gives Up More Ground at Investor's Business Daily
Nov-26-14 05:40PM  Stock Market Today: Top Biotech Is Near Buy Point at Investor's Business Daily
Nov-13-14 06:44AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
06:00AM  Professor Katherine J. Klein Joins The United Therapeutics Corporation Board Of Directors PR Newswire
Nov-03-14 08:45AM  United Therapeutics downgraded by Argus Briefing.com
Oct-30-14 08:08PM  10-Q for United Therapeutics Corp. Company Spotlight
07:59PM  Apple CEO publicly acknowledges that he's gay AP
Oct-29-14 11:50AM  United Therapeutics Falls on Q3 Loss, Revenues Miss Zacks
Oct-28-14 07:07AM  Q3 2014 United Therapeutics Corp Earnings Release - Before Market Open CCBN
06:27AM  United Therapeutics reports 3Q loss AP
06:05AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:04AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports Third Quarter 2014 Financial Results PR Newswire
Oct-22-14 05:01PM  Biotechs Show Fed Chief's Not Much Of A Stock Analyst at Investor's Business Daily
Oct-21-14 06:00AM  United Therapeutics Corporation To Announce Third Quarter 2014 Financial Results Before Market Open On Tuesday, October 28, 2014 PR Newswire
Oct-14-14 05:05PM  Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 Zacks
10:27AM  J&J Beats Q3 Earnings on Strong Drug Sales, Ups View Zacks
Sep-26-14 03:07PM  Biotech's future: The Government is key Yahoo Finance
Sep-25-14 12:34PM  Artificial intelligence doppelgangers and life in outer space closer than you think Yahoo Finance
08:38AM  Highest-paid female CEO used to be a man Yahoo Finance
Sep-24-14 09:36AM  Can the Uptrend Continue for United Therapeutics (UTHR)? Zacks
Sep-23-14 05:21PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
08:10AM  Moving Average Crossover Alert: United Therapeutics (UTHR) Zacks
Sep-22-14 05:11PM  Today's Market Thorns, Roses and All Time Highs... Yahoo Finance Blogs
Sep-17-14 07:30AM  Axsome Therapeutics Announces Appointments to Its Board of Directors GlobeNewswire
Sep-16-14 03:00AM  Pluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market GlobeNewswire
Sep-15-14 05:32PM  Today's Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
11:19AM  Hedge fund offers $1 million to cure...aging? at CNBC
Sep-10-14 04:20PM  Spectrum Pharmaceuticals to Advance Neutropenia Drug Zacks
Sep-09-14 03:50PM  Pluristem & United Therapeutics Progress with Phase I Study Zacks
Sep-03-14 04:20PM  Arena Pharmaceuticals' APD811 Gets Orphan Drug Status Zacks
09:10AM  Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Zacks
Sep-02-14 05:25PM  United Therapeutics Soars on Remodulin Patent Case Win Zacks
07:58AM  United Therapeutics (UTHR) Shares March Higher, Can It Continue? Zacks
Aug-29-14 04:21PM  United Therapeutics Legal Victory Sends Stock Flying at Investor's Business Daily +28.51%
02:21PM  United Therapeutics Up 27% as Patent Win 'Close to a Best Case Scenario' at Barrons.com
02:02PM  United Therapeutics rises on drug-patent ruling AP
12:49PM  District Court Decision Received In Remodulin Patent Case PR Newswire
Aug-26-14 07:50AM  Catalyst Pharmaceutical Partners (CPRX) Worth Watching: Stock Up 10.3% Zacks
Aug-25-14 11:05AM  Roche Buying InterMune for $8.3 Billion; Investors Want More Pharma Deals StockTwits
Aug-22-14 04:40PM  OncoGenex's Custirsen Passes First Interim Futility Analysis Zacks
08:25AM  Flamel Technologies SA (FLML) in Focus: Stock Rises 8% Zacks
Aug-21-14 08:56AM  Gilead (GILD) Hits 52-Week High Thanks to Sovaldi Zacks
Aug-20-14 05:21PM  Alcobra Starts Patient Enrollment for Mid-Stage Study on MDX Zacks
08:40AM  Salix Pharmaceuticals (SLXP) Jumps: Stock Moves 15.5% Higher Zacks
06:51AM  Can United Therapeutics (UTHR) Keep the Earnings Streak Alive This Quarter? Zacks
Aug-14-14 02:30PM  Rigel's R348 Fails in Phase II Study, Shares Down 13.6% Zacks
Jul-31-14 12:20PM  United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat Zacks
Jul-30-14 10:56AM  Perilous Reversal Watch: United Therapeutics (UTHR) at TheStreet -5.01%
07:08AM  United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session Zacks
Jul-29-14 07:07AM  Q2 2014 United Therapeutics Earnings Release - Before Market Open CCBN +8.10%
06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:03AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports Second Quarter 2014 Financial Results PR Newswire
Jul-22-14 06:00AM  United Therapeutics Corporation To Announce Second Quarter 2014 Financial Results Before Market Open On Tuesday, July 29, 2014 PR Newswire
Jul-10-14 03:43PM  Supernus Up on Non-Dilutive Royalty Deal Zacks
Jul-09-14 05:00PM  Pluristem Initiates Trial in South Korea Zacks
Jul-08-14 07:30AM  Supernus to Receive $30 Million in Non-Dilutive Royalty Deal GlobeNewswire
05:47AM  United Therapeutics draws bulls optionMONSTER
Jun-27-14 09:14AM  Today's Top Biotech Stocks: Bristol-Myers Squibb, United Therapeutics and Vertex Pharmaceuticals at Motley Fool
06:02AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc EDGAR Online
06:00AM  United Therapeutics Announces Additional $500 Million Share Repurchase Program PR Newswire
Jun-19-14 01:18PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into United Therapeutics Corporation Regarding Possible Breaches of Fiduciary Duty Business Wire
Jun-16-14 09:49AM  United Therapeutics (UTHR) Marked As A Dead Cat Bounce Stock at TheStreet
07:26AM  Weakness Seen in United Therapeutics (UTHR): Stock Tumbles 8.0% Zacks
Jun-13-14 04:46PM  Can Pig Lungs Keep Growth Flying for United Therapeutics Shareholders? at Motley Fool -7.97%
Jun-09-14 02:34PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into United Therapeutics Corporation Regarding Possible Breaches of Fiduciary Duty PR Newswire
May-21-14 05:34PM  [video] Momentum trades alive: ARCB, UTHR at CNBC
May-20-14 05:00PM  Supernus Receives $2 Million Milestone for United Therapeutics' Launch of Orenitram(TM) GlobeNewswire
11:19AM  Why I'm Long Supernus, A Small Specialty Pharma Company at Seeking Alpha
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KURZWEIL RAYDirectorFeb 27Option Exercise51.7715,000776,55015,000Feb 27 09:20 PM
Thompson Tommy GDirectorFeb 27Option Exercise52.657,500394,8757,500Feb 27 08:32 PM
PATUSKY CHRISTOPHERDirectorFeb 27Option Exercise51.777,500388,2757,500Feb 27 09:15 PM
Thompson Tommy GDirectorFeb 27Sale153.637,5001,152,2380Feb 27 08:32 PM
PATUSKY CHRISTOPHERDirectorFeb 27Sale155.057,5001,162,8750Feb 27 09:15 PM
KURZWEIL RAYDirectorFeb 27Sale155.0515,0002,325,7500Feb 27 09:20 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 26Option Exercise32.379,662312,7855,787Feb 26 05:10 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 26Sale155.239,6621,499,868240Feb 26 05:10 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 25Option Exercise63.222,211139,7792,451Feb 25 09:07 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 25Sale159.352,211352,317240Feb 25 09:07 PM
JEFFS ROGERPresident & Co-CEOFeb 24Option Exercise50.0910,000500,90011,234Feb 24 06:51 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerFeb 24Option Exercise50.091,45873,0312,611Feb 24 06:54 PM
JEFFS ROGERPresident & Co-CEOFeb 24Sale155.1610,0001,551,6001,234Feb 24 06:51 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerFeb 24Sale155.161,458226,2231,153Feb 24 06:54 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 23Option Exercise52.652,592136,4692,832Feb 23 08:33 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 23Sale156.082,592404,550240Feb 23 08:33 PM
Ferrari John MaximCFOFeb 19Option Exercise57.1510,000571,50010,407Feb 19 09:10 PM
MAHON PAUL AEVP & General CounselFeb 19Option Exercise33.146,000198,84040,832Feb 19 09:16 PM
Ferrari John MaximCFOFeb 19Sale155.7210,0001,557,200407Feb 19 09:10 PM
MAHON PAUL AEVP & General CounselFeb 19Sale155.726,000934,32034,832Feb 19 09:16 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 18Option Exercise52.652,211116,4092,451Feb 24 04:49 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 18Sale154.902,211342,479240Feb 24 04:49 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 17Option Exercise52.652,592136,4692,832Feb 18 08:17 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerFeb 17Option Exercise50.094,000200,3605,153Feb 18 08:22 PM
JEFFS ROGERPresident & Co-CEOFeb 17Option Exercise50.0910,000500,90011,234Feb 18 08:26 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerFeb 17Sale155.144,000620,5601,153Feb 18 08:22 PM
JEFFS ROGERPresident & Co-CEOFeb 17Sale155.1410,0001,551,4001,234Feb 18 08:26 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 17Sale152.282,592394,703240Feb 18 08:17 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 12Option Exercise32.379,662312,7855,787Feb 13 07:32 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 12Sale146.019,6621,410,766240Feb 13 07:32 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 11Option Exercise63.222,211139,7792,451Feb 11 07:58 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 11Sale147.292,211325,660240Feb 11 07:58 PM
JEFFS ROGERPresident & Co-CEOFeb 10Option Exercise50.0910,000500,90011,234Feb 11 08:19 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerFeb 10Option Exercise50.094,000200,3605,153Feb 11 08:07 PM
JEFFS ROGERPresident & Co-CEOFeb 10Sale146.6810,0001,466,8001,234Feb 11 08:19 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerFeb 10Sale146.684,000586,7201,153Feb 11 08:07 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 09Option Exercise52.652,592136,4692,832Feb 09 05:17 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 09Sale143.322,592371,481240Feb 09 05:17 PM
MAHON PAUL AEVP & General CounselFeb 05Option Exercise33.146,000198,84040,832Feb 06 08:36 AM
Ferrari John MaximCFOFeb 05Option Exercise57.1510,000571,50010,407Feb 06 08:42 AM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 05Option Exercise32.379,662312,7855,787Feb 05 06:56 PM
DWEK RAYMONDDirectorFeb 05Option Exercise31.173,00093,5103,000Feb 05 07:00 PM
CAUSEY CHRISTOPHERDirectorFeb 05Option Exercise41.143,000123,4203,733Feb 05 07:04 PM
MAHON PAUL AEVP & General CounselFeb 05Sale141.926,000851,52034,832Feb 06 08:36 AM
Ferrari John MaximCFOFeb 05Sale141.9210,0001,419,200407Feb 06 08:42 AM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 05Sale141.189,6621,364,117240Feb 05 06:56 PM
DWEK RAYMONDDirectorFeb 05Sale140.413,000421,2170Feb 05 07:00 PM
CAUSEY CHRISTOPHERDirectorFeb 05Sale140.403,000421,190733Feb 05 07:04 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 04Option Exercise63.222,211139,7792,351Feb 05 06:56 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 04Sale140.582,111296,756240Feb 05 06:56 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerFeb 03Option Exercise50.094,000200,3605,153Feb 04 08:02 PM
JEFFS ROGERPresident & Co-CEOFeb 03Option Exercise50.0910,000500,90011,234Feb 04 08:06 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerFeb 03Sale141.994,000567,9601,153Feb 04 08:02 PM
JEFFS ROGERPresident & Co-CEOFeb 03Sale141.9910,0001,419,9001,234Feb 04 08:06 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 02Option Exercise52.652,592136,4692,732Feb 04 04:24 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 02Sale141.142,592365,829140Feb 04 04:24 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 29Option Exercise32.379,662312,7855,687Jan 30 05:43 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 29Sale143.299,6621,384,502140Jan 30 05:43 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 28Option Exercise63.222,211139,7792,351Jan 28 05:05 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 28Sale145.492,211321,684140Jan 28 05:05 PM
JEFFS ROGERPresident & Co-CEOJan 27Option Exercise50.0910,000500,90011,234Jan 28 04:28 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 27Option Exercise50.094,000200,3605,153Jan 28 04:32 PM
JEFFS ROGERPresident & Co-CEOJan 27Sale147.1910,0001,471,9001,234Jan 28 04:28 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 27Sale147.194,000588,7601,153Jan 28 04:32 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 26Option Exercise52.652,592136,4692,732Jan 27 07:27 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 26Sale145.892,592378,136140Jan 27 07:27 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 22Option Exercise32.379,662312,7855,687Jan 22 09:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 22Sale146.649,6621,416,862140Jan 22 09:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 21Option Exercise63.222,211139,7792,351Jan 22 09:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 21Sale147.262,211325,602140Jan 22 09:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 20Option Exercise52.652,592136,4692,732Jan 20 05:52 PM
JEFFS ROGERPresident & Co-CEOJan 20Option Exercise50.0910,000500,90011,234Jan 22 08:31 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 20Option Exercise50.094,000200,3605,153Jan 22 08:37 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 20Sale145.062,592375,993140Jan 20 05:52 PM
JEFFS ROGERPresident & Co-CEOJan 20Sale146.4810,0001,464,8001,234Jan 22 08:31 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 20Sale146.484,000585,9201,153Jan 22 08:37 PM
Ferrari John MaximCFOJan 15Option Exercise51.3722,5001,155,82522,907Jan 15 09:21 PM
MAHON PAUL AEVP & General CounselJan 15Option Exercise33.146,000198,84040,832Jan 15 09:31 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 15Option Exercise32.379,662312,7855,687Jan 15 09:44 PM
Ferrari John MaximCFOJan 15Sale137.8422,5003,101,400407Jan 15 09:21 PM
MAHON PAUL AEVP & General CounselJan 15Sale137.846,000827,04034,832Jan 15 09:31 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 15Sale137.519,6621,328,670140Jan 15 09:44 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 14Option Exercise63.222,211139,7792,351Jan 14 07:15 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 14Sale135.182,211298,887140Jan 14 07:15 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 13Option Exercise50.093,000150,2704,153Jan 14 07:20 PM
JEFFS ROGERPresident & Co-CEOJan 13Option Exercise50.0910,000500,90011,234Jan 14 07:27 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 13Sale134.713,000404,1301,153Jan 14 07:20 PM
JEFFS ROGERPresident & Co-CEOJan 13Sale134.7110,0001,347,1001,234Jan 14 07:27 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 12Option Exercise52.652,592136,4692,732Jan 13 04:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 12Sale132.002,592342,148140Jan 13 04:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 08Option Exercise32.379,662312,7855,687Jan 08 08:00 PM
PATUSKY CHRISTOPHERDirectorJan 08Option Exercise41.145,000205,7005,000Jan 12 08:35 AM
ROTHBLATT MARTINE AChairman & Co-CEOJan 08Sale128.319,6621,239,695140Jan 08 08:00 PM
PATUSKY CHRISTOPHERDirectorJan 08Sale128.135,000640,6500Jan 12 08:35 AM
ROTHBLATT MARTINE AChairman & Co-CEOJan 07Option Exercise63.222,211139,7792,351Jan 07 08:48 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 07Sale126.042,211278,683140Jan 07 08:48 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 06Option Exercise49.663,000148,9753,653Jan 07 08:23 PM
JEFFS ROGERPresident & Co-CEOJan 06Option Exercise50.097,500375,6758,734Jan 07 08:31 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJan 06Sale124.933,000374,7901,153Jan 07 08:23 PM
JEFFS ROGERPresident & Co-CEOJan 06Sale124.937,500936,9751,234Jan 07 08:31 PM